688506.SHG Sichuan Biokin Pharmaceutical Co. Ltd. A
- Market cap
- CNY 110B
- P/E
- -
- P/B
- 19.43x
- ROE
- -17.2%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688506.SHG undervalued?
Graham numberThe Graham number of Sichuan Biokin Pharmaceutical Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sichuan Biokin Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Sichuan Biokin Pharmaceutical Co. Ltd. A yet.
Sichuan Biokin Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, manufacture, and sale of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.
Full company profileSichuan Biokin Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sichuan Biokin Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 797M | 703M | 562M | 5.82B | 2.52B | 2.79B |
| Gross Profit | 599M | 471M | 333M | 5.56B | 2.29B | 2.58B |
| Operating Income | -93.3M | -253M | -742M | 3.74B | -743M | -666M |
| EBITDA | - | -204M | -680M | 4.10B | -533M | -655M |
| Net Income | -100.0M | -282M | -780M | 3.71B | -1.05B | -940M |
| EPS | -0.28 | -0.70 | -1.95 | 9.25 | -2.55 | -2.28 |
| Balance Sheet | ||||||
| Total Assets | 951M | 1.99B | 1.43B | 7.14B | 11.4B | 13.4B |
| Total Liabilities | 620M | 1.06B | 1.27B | 3.25B | 4.83B | 7.91B |
| Shareholders' Equity | 332M | 934M | 152M | 3.89B | 6.62B | 5.46B |
| Cash & Short-term Investments | 154M | 1.00B | 404M | 3.22B | 5.18B | 4.51B |
| Cash Flow | ||||||
| Operating Cash Flow | -135M | -259M | -615M | 4.06B | -798M | - |
| Capital Expenditure | 44.6M | 34.6M | 81.9M | 83.9M | 264M | 1.10B |
| Free Cash Flow | -180M | -293M | -697M | 3.97B | -1.06B | -3.99B |
| Ratios | ||||||
| ROE | -30.1% | -30.2% | -513.9% | 95.4% | -15.9% | -17.2% |
| ROA | -10.5% | -14.2% | -54.8% | 51.9% | -9.2% | -7.0% |
| Net Profit Margin | -12.6% | -40.2% | -138.9% | 63.7% | -41.8% | -33.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sichuan Biokin Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.07%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 78.4M | 0.19 | - |
| 2024 | CNY 38.4M | 0.10 | 1.0% |
| 2023 | CNY 18.8M | 0.05 | - |
| 2022 | CNY 12.6M | 0.03 | - |
| 2021 | CNY 27.0M | 0.07 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sichuan Biokin Pharmaceutical Co. Ltd. A
- Insiders 80.47%
- Institutions 10.61%
- Public & others 8.92%
- Shares outstanding 413M
- Free float 77.5M
Sichuan Biokin Pharmaceutical Co. Ltd. A company profile
- Company name
- Sichuan Biokin Pharmaceutical Co. Ltd. A
- Ticker
- 688506.SHG
- ISIN
- CNE100006FN4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 3,198
- Fiscal year end
- December
- Address
- Block B, Gaoxin International Plaza, Chengdu, China
- Phone
- 86 28 8518 3639
- Website
- baili-pharm.com
About Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, manufacture, and sale of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.
Sichuan Biokin Pharmaceutical Co. Ltd. A management
6- Dr. Yi ZhuChairman, GM & Chief Scientific Officer · born 1963
- Ms. Suya ZhangCFO, Executive Deputy GM, Accounting Supervisor & Director · born 1955
- Dr. Hai ZhuExecutive Director · born 1988
- Mr. Shi ZhuoDeputy GM & Executive Director · born 1985
- Dr. Weili WanDeputy GM & Executive Director · born 1989
- Yong HeDeputy General Manager · born 1975